D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
154,100
+1,300 (0.85%)
Jul 18, 2025, 3:30 PM KST
353.90%
Market Cap1.67T
Revenue (ttm)10.75B
Net Income (ttm)-32.98B
Shares Out10.82M
EPS (ttm)-3,151.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume329,087
Average Volume324,183
Open150,300
Previous Close152,800
Day's Range146,800 - 155,900
52-Week Range25,500 - 157,200
Betan/a
RSI72.87
Earnings DateAug 12, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.